disappointing TNBC trial results
Printed From: TNBC Foundation
Category: TNBC Forums
Forum Name: Let's Talk About Chemotherapy
Forum Description: A place to discuss Chemotherapy
URL: http://forum.tnbcfoundation.org/forum_posts.asp?TID=13853
Printed Date: Mar 26 2026 at 8:23pm
Software Version: Web Wiz Forums 12.01 - http://www.webwizforums.com
Topic: disappointing TNBC trial results
Posted By: SagePatientAdvocates
Subject: disappointing TNBC trial results
Date Posted: Jan 10 2022 at 11:45am
|
Dear TNBC family, I received an article from MedPage today https://www.medpagetoday.com/reading-room/asco/breast-cancer/96473?xid=NL_ASCORR_2022-01-10&eun=g5564105d39r&pos=" rel="nofollow - https://www.medpagetoday.com/reading-room/asco/breast-cancer/96473?xid=NL_ASCORR_2022-01-10&eun=g5564105d39r&pos= Hope you all can open it... Here is a brief summary based on a statement from Dr. Ingrid Mayer an excellent TNBC specialist at Vanderbilt i Nashville, TN. – Should discourage use of adjuvant platinum in residual TNBC post-neoadjuvant chemo, she saysby https://www.medpagetoday.com/people/jm2952/Jeff-Minerd" rel="nofollow - Jeff Minerd , Contributing Writer, MedPage Today January 4, 2022 https://www.facebook.com/sharer/sharer.php?u=https://www.medpagetoday.com/reading-room/asco/breast-cancer/96473&t=Ingrid%20Mayer,%20MD,%20on%20the%20Disappointing%20Results%20of%20the%20EA1131%20TNBC%20Trial" rel="nofollow - https://twitter.com/intent/tweet?original_referer=https%3A%2F%2Fwww.medpagetoday.com%2Freading-room%2Fasco%2Fbreast-cancer%2F96473&source=tweetbutton&text=Ingrid%20Mayer%2C%20MD%2C%20on%20the%20Disappointing%20Results%20of%20the%20EA1131%20TNBC%20Trial&url=https%3A%2F%2Fwww.medpagetoday.com%2Freading-room%2Fasco%2Fbreast-cancer%2F96473" rel="nofollow - https://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fwww.medpagetoday.com%2Freading-room%2Fasco%2Fbreast-cancer%2F96473&summary=Ingrid%20Mayer,%20MD,%20on%20the%20Disappointing%20Results%20of%20the%20EA1131%20TNBC%20Trial&source=MedPage%20Today" rel="nofollow - This Reading Room is a collaboration between MedPage Today® and:  Platinum-based agents have been used as adjuvant therapy for patients with residual triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy, based on clinical trial data showing improved pathological complete response (pCR) rates. Newer data, however, should discourage this practice, scientists said. The https://www.clinicaltrials.gov/ct2/show/NCT02445391" rel="nofollow - ECOG-ACRIN EA1131 trial found that platinum-based chemotherapy did not extend invasive disease-free survival compared with capecitabine in patients with TNBC residual disease following neoadjuvant chemotherapy, regardless of the cancer subtype, and was associated with more severe toxicity. Steve ------------- I am a BRCA1+ grandson, son and father of women affected by breast/oc-my daughter inherited mutation from me, and at 36, was dx 2004 TNBC I am a volunteer patient advocate with SAGE Patient Advocates |